COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 2220: Articles 22191-22200  | Next

Impact of COVID-19 lockdown on psychosocial factors, health, and lifestyle in Scottish octogenarians: the Lothian Birth Cohort 1936 Study
Taylor, A. M., Page, D., Okely, J. A., Corley, J., Welstead, M., Skarabela, B., Redmond, P., Russ, T. C., Cox, S. R.
10.1101/2020.10.01.20203711 — Posted: 2020-10-02
Performance of a rapid SARS-COV-2 serology test in whole blood and separated plasma
Vemulapati, S.
10.1101/2020.10.02.20199083 — Posted: 2020-10-02
A small interfering RNA (siRNA) database for SARS-CoV-2
Medeiros, I. G., Khayat, A. S., Stransky, B., dos Santos, S. E. B., Assumpcao, P. P., de Souza, J. E. S.
10.1101/2020.09.30.321596 — Posted: 2020-10-01
Transcriptional differences for COVID-19 Disease Map genes between males and females indicate a different basal immunophenotype relevant to the disease
Liu, T., Balzano-Nogueira, L., Lleo, A., Conesa, A.
10.1101/2020.09.30.321059 — Posted: 2020-10-01
Thiopurines activate an antiviral unfolded protein response that blocks viral glycoprotein accumulation in cell culture infection model
Slaine, P. D., Kleer, M., Duguay, B., Pringle, E. S., Kadijk, E., Ying, S., Balgi, A. D., Roberge, M., McCormick, C., Khaperskyy, D. A.
10.1101/2020.09.30.319863 — Posted: 2020-10-01
SARS-CoV-2 viral budding and entry can be modeled using virus-like particles
Plescia, C. B., David, E. A., Patra, D., Sengupta, R., Amiar, S., Su, Y., Stahelin, R. V.
10.1101/2020.09.30.320903 — Posted: 2020-10-01
SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro
Hsu, A. C.-Y., Wang, G., Reid, A. T., Veerati, P. C., Pathinayake, P. S., Daly, K., Mayall, J. R., Hansbro, P. M., Horvat, J. C., Wang, F., Wark, P. A.
10.1101/2020.09.30.317818 — Posted: 2020-10-01 Discussion: Onsite | Offsite
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Jones, B. E., Brown-Augsburger, P. L., Corbett, K. S., Westerndorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., Higgs, R. E., Balasubramaniam, D., Wang, L., Bidshahri, R., Kraft, L., Hwang, Y., Zentelis, S., Jepson, K. R., Goya, R., Smith, M. A., Collins, D. W., Hinshaw, S. J., Tycho, S. A., Pellacani, D., Xiang, P., Muthuraman, K., Sobhanifar, S., Piper, M. H., Triana, F. J., Hendle, J., Pustilnik, A., Adams, A. C., Berens, S. J., Baric, R. S., Martinez, D. R., Cross, R. W., Geisbert, T. W., Borisevich, V., Abiona, O., Belli, H. M., de Vries, M., Mohamed, A., Dittmann, M., Samanovic, M., Mulligan, M. J., Goldsmith, J. A., Hsieh, C.-L., Johnson, N. V., Wrapp, D., McLellan, J. S., Barnhart, B. C., Graham, B. S., Mascola, J. R., Hansen, C. L., Falconer, E.
10.1101/2020.09.30.318972 — Posted: 2020-10-01
SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection.
Robertson, L. J., Moore, J. S., Blighe, K., Ng, K. Y., Quinn, N., Jennings, F., Warnock, G., Sharpe, P., Clarke, M., Maguire, K., Rainey, S., Price, R., Burns, W., Kowalczyk, A., Awuah, A., McNamee, S., Wallace, G., Sager, S., Chao Shern, C., Nesbit, M. A., McLaughlin, J., Moore, T.
10.1101/2020.09.29.20201509 — Posted: 2020-10-01
SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies
O'Nions, J., Muir, L., Zheng, J., Rees-Spear, C., Rosa, A., Earl, C., Cherepanov, P., Gupta, R., Khwaja, A., Jolly, C., McCoy, L. E.
10.1101/2020.09.29.20202846 — Posted: 2020-10-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).